ResearchRSSToday
Researchers found that simple gut biopsies might detect signs of Parkinson's disease years before a person develops movement problems or other symptoms. They discovered that more than half of people with digestive issues but no diagnosed neurological disease showed protein misfolding in their gut tissue. This could allow doctors to identify people at high risk for Parkinson's much earlier than currently possible.
WHY IT MATTERSIf validated, routine gut biopsies could identify Parkinson's disease risk years before symptoms appear, potentially allowing earlier intervention when treatments might be most effective.
ResearchRSSYesterday
Scientists discovered that in Parkinson's disease, clumps of a toxic protein called alpha-synuclein damage not just brain cells but also the tiny blood vessels that supply the brain. These two types of damage likely work together to make the disease worse over time. This finding helps explain why Parkinson's affects the brain in multiple ways.
WHY IT MATTERSUnderstanding that blood vessel damage contributes to Parkinson's progression could lead to new treatments that protect blood vessels, potentially slowing disease advancement beyond current approaches that only target brain cell damage.
ResearchRSS2 days ago
A new study found that women with Parkinson's disease are much less likely than men to choose a brain surgery called deep brain stimulation (DBS). The main reason is that women often worry about being a burden on their family and don't have as much support available to help them through the procedure and recovery.
WHY IT MATTERSIf you're a woman with Parkinson's considering DBS, understanding that support concerns are common may help you have more honest conversations with your doctor and family about what you actually need to move forward with treatment.
ResearchRSSApr 22
Scientists at Florida International University found a compound called CTS2444-32 that may help slow Parkinson's disease by improving how mitochondria (the energy centers of cells) work. The compound works by reducing a protein called DRP1 that controls mitochondrial function, which helps prevent toxic proteins from building up in the brain—a key problem in Parkinson's.
WHY IT MATTERSIf CTS2444-32 proves effective in human trials, it could offer Parkinson's patients a new treatment option that targets the disease's underlying cause rather than just managing symptoms.
ResearchRSSApr 22
Researchers found that a Parkinson's disease medication called Crexont helped patients spend more time feeling better and less time experiencing symptoms when they switched from other levodopa treatments. The study showed improvements in movement control and daily functioning across different patient groups. This is early-stage research being presented at a medical conference.
WHY IT MATTERSIf you take levodopa for Parkinson's and struggle with 'off' periods when symptoms return between doses, Crexont may offer a way to extend your good symptom control time throughout the day.